<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01051518</url>
  </required_header>
  <id_info>
    <org_study_id>COR-2006-02</org_study_id>
    <nct_id>NCT01051518</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of Percutaneous Implantation of the Medtronic CoreValve Aortic Valve Prosthesis (18Fr-Study)</brief_title>
  <official_title>Clinical Evaluation of Percutaneous Implantation of the CoreValve Aortic Valve Prosthesis. Safety and Performance Study on Patients at High Risk for Surgical Valve Replacement (18Fr Safety and Efficacy Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Bakken Research Center</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Cardiovascular</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigation concerns a prospective, multicenter, single arm safety and performance
      study evaluating the Medtronic CoreValve system. Approximately 120 patients presenting with
      symptomatic aortic native valve stenosis necessitating valve replacement which are considered
      poor surgical candidates, with a high surgical risk, as attested to by both the surgeon and
      the cardiologist are recruited in the study.

      Safety and performance will be evaluated at discharge and at 30 days post-procedure. Valve
      performance and placement will be followed up at 3 and 6 months post-procedure. Further
      long-term patient follow-up visits will be performed at 12, 24, 36 and 48 months
      post-procedure.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite Major Adverse Events (MAE)</measure>
    <time_frame>Discharge and 30-days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">126</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <arm_group>
    <arm_group_label>CoreValve</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Medtronic CoreValve System</intervention_name>
    <description>Transcatheter Aortic Valve</description>
    <arm_group_label>CoreValve</arm_group_label>
    <other_name>Medtronic CoreValve Trancatheter Aortic Valve</other_name>
    <other_name>Medtronic CoreValve Percutaneous Aortic Valve</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Native aortic valve disease, defined as valve stenosis with an aortic valve area &lt;1cm²
             (&lt;0.6cm2/m2) as determined by echocardiographic measure,

          -  ≥ 75 years, or

          -  Surgical risk calculated with logistic EuroSCORE ≥ 15 %, or

          -  One or two (but not more than 2) of the following complicating factors:

               1. Cirrhosis of the liver (Child class A or B),

               2. Pulmonary insufficiency : Forced expiratory volume in one second (FEV1) &lt; 1
                  liter,

               3. Previous cardiac surgery (Coronary artery bypass grafting (CABG), valvular
                  surgery),

               4. Pulmonary hypertension &gt; 60 mmHg and high risk of cardiac surgery other than
                  valve replacement,

               5. Porcelain aorta

               6. Recurrent pulmonary embolus,

               7. Right ventricular insufficiency,

               8. Thoracic burning sequelae contraindicating open chest surgery,

               9. History of mediastinum radiotherapy,

              10. Severe connective tissue disease resulting in a contraindication to surgery,

              11. Cachexia (BMI ≤ 18 kg/m²),

          -  Aortic valve annulus diameter is ≥ 20 mm and ≤ 27 mm as determined by
             echocardiographic measure,

          -  Ascending aorta diameter £ 45 mm at the sino-tubular junction, and

          -  Signed Informed Consent.

        Exclusion Criteria:

          -  Known hypersensitivity or contraindication to aspirin, heparin, ticlopidine,
             clopidogrel, Nitinol, or sensitivity to contrast media which cannot be adequately
             pre-medicated,

          -  Any sepsis, including active endocarditis,

          -  Recent myocardial infarction (&lt; 30 days),

          -  Percutaneous coronary or vascular intervention within 15 days prior to the study
             procedure, or scheduled during or within 30 days after the study procedure,

          -  Any left ventricular or atrial thrombus diagnosed by echocardiography,

          -  Uncontrolled atrial fibrillation (heart rate greater than 100 bpm),

          -  Mitral or tricuspid valvular insufficiency ( &gt; grade II),

          -  Previous aortic valve replacement (mechanical valve OR stented bioprosthetic valve),

          -  Any condition considered as contraindication for extracorporeal assistance,

          -  Evolutive or recent CVA (cerebro vascular accident),

          -  Poly arterial patients with either:

               1. Femoral, iliac or aortic vascular condition (e.g. stenosis, tortuosity), that
                  make insertion and endovascular access to the aortic valve impossible, or

               2. Symptomatic carotid or vertebral arteries narrowing (&gt; 70%) disease, or

               3. Abdominal or thoracic aortic aneurysm,

          -  Bleeding diathesis or coagulopathy, or patient who will refuse blood transfusion,

          -  Evolutive disease with life expectancy less than one year,

          -  Creatinine clearance &lt; 20 ml/min,

          -  Pregnancy, and

          -  Enrolled in another investigational study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>75 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>E. Grube, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helios Heart Center Siegburg, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>G. Schuler, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Herzzentrum Universitat Leipzig, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>R. Bonan, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Cardiologie de Montreal, Canada</affiliation>
  </overall_official>
  <overall_official>
    <last_name>J. Kovac, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Glenfield Hospital Leicester, UK</affiliation>
  </overall_official>
  <overall_official>
    <last_name>P. Serruys, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus MC Rotterdam, Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>M. Labinaz, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Ottawa Heart Institute, Canada</affiliation>
  </overall_official>
  <overall_official>
    <last_name>P den Heijer, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Amphia Hospital Breda, Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>M Mullen, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Brompton &amp; Harefield NHS Trust London, UK</affiliation>
  </overall_official>
  <overall_official>
    <last_name>W. Tymchak, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alberta Hospital, Canada</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cardiologie de Montreal</name>
      <address>
        <city>Montreal</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Ottawa Heart Institute</name>
      <address>
        <city>Ottawa</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Leipzig GmbH</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HELIOS Heart Center Siegburg</name>
      <address>
        <city>Siegburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amphia Hospital</name>
      <address>
        <city>Breda</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glenfield Hospital</name>
      <address>
        <city>Leicester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brompton &amp; Harefield NHS Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.medtronic.com</url>
  </link>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2010</study_first_submitted>
  <study_first_submitted_qc>January 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2010</study_first_posted>
  <last_update_submitted>June 20, 2017</last_update_submitted>
  <last_update_submitted_qc>June 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>October 27, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

